Limitations, agreements, and source contact

Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer · Source last updated 2024-06-26

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

true

point Of Contact

email

Sara_Tolaney@dfci.harvard.edu

organization

Dana Farber Cancer Institute

phone

617-632-3800

title

SARA TOLANEY, MD, MPH

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice